209 results about "Urinary Bladder Cancer" patented technology

The invention discloses a paris polyphylla extract which is prepared by the following steps: extracting crushed paris polyphylla for 1-3 times by adopting a cyclodextrin solution at 30-70 DEG C under ultrasonic waves, collecting and combining an extracting solution, separating and purifying the extracting solution through macroporous resin, eluting the extracting solution through an ethanol solution with the volume concentration of 70%, and concentrating and drying the eluent, thereby obtaining the paris polyphylla extract. The paris polyphylla extract is applied to treatment of bladder cancer, experimental results show that the paris polyphylla extract has an obvious inhibiting effect on proliferation of human bladder cancer cells T24 and UM-UC-3, a theoretical basis is provided for deep research on the anti-tumor action mechanism of paris polyphylla, and the paris polyphylla extract is of great significance in revealing research on anti-tumor effective active ingredients of paris polyphylla and has a wide application prospect. The invention provides a new way and means for treating tumors.

The invention discloses a bladder cancer level evaluation method and device based on radiomics and a storage medium. The bladder cancer level evaluation method and device are used for improving bladder cancer level evaluation accuracy and reliability. Obtaining a multi-parameter MRI image of the bladder cancer, wherein the multi-parameter MRI image comprises a T2 weighted image, a diffusion weighted image and a dynamic contrast enhanced image; performing tumor focus part sketching on the multi-parameter MRI image; respectively carrying out feature extraction on the delineated T2 weighted image, diffusion weighted image and dynamic contrast enhanced image by using a radiomics package to generate a bladder cancer feature set; performing feature difference screening on the bladder cancer feature set according to the clinical diagnosis tag; carrying out dimension reduction processing on the screened bladder cancer feature set; constructing a single-parameter MRI classification model and a multi-parameter joint classification model according to the bladder cancer feature set after dimension reduction; and using the single-parameter MRI classification model and the multi-parameter joint classification model to jointly evaluate the bladder cancer level of the to-be-detected data.

The invention belongs to the technical field of medical data processing, and particularly relates to a bladder cancer vessel tumor embolus assessment method and system based on multi-modal feature fusion, and the optimization method comprises the steps: obtaining and preprocessing the pathological information and image data of a bladder cancer patient, extracting a CT image corresponding to a tumor, and determining a region of interest; image omics features are extracted from the region of interest of the CT image, and deep learning features are extracted from the maximum tumor cross section; carrying out feature selection processing on the obtained radiomics features and deep learning features, and inputting the processed features into a fusion model; and outputting a probability value of'lymphatic vessel invasion 'by the fusion model to obtain an evaluation result. A multi-modal machine learning model is constructed by fusing radiomics features and deep learning features extracted from a CT image, and the objective of the invention is to noninvasively and accurately evaluate the lymphatic vessel infringement state of bladder cancer before an operation, so that a key basis is provided for clinical individualized treatment decision-making.

A chitosan-heparin nanomotor and a method for producing same are disclosed. A STING agonist-encapsulated urease-based chitosan-heparin nanomotor delivers the STING agonist directly to bladder mucosal cells in the bladder, and thus can induce an immune response.

The invention discloses a bladder cancer individualized diagnosis and treatment method based on multi-modal magnetic resonance image fusion and a related device. The method comprises the following steps: acquiring multi-modal image data of a bladder tumor of a patient; extracting quantitative image features related to staging and grading of the bladder cancer according to the multi-modal image data; dynamic curve characteristics of dynamic contrast enhanced magnetic resonance imaging DCE-MRI are extracted according to the quantitative image characteristics, the dynamic curve characteristics comprise a rising slope, peak arrival time and an area under a curve AUC, and heterogeneity of the dynamic curve characteristics in different areas of the bladder cancer tumor is analyzed to form a DCE-MRI characteristic set; the muscle layer infiltration depth and range of the bladder cancer tumor and the surrounding tissue invasion condition are quantitatively evaluated, and the individualized resection depth and range and the operation method of the transurethral bladder tumor are predicted. According to the method, the multi-modal magnetic resonance images are fused, the quantitative image features and the dynamic curve features are extracted, the muscle layer infiltration depth and the surrounding tissue invasion condition of the bladder cancer tumor are quantitatively evaluated, and an individualized diagnosis and treatment scheme is achieved.

The invention relates to the technical field of biomedical detection, in particular to a urinary tract epithelium cancer detection marker composition based on ONECUT2 and DMRTA2 gene methylation, which comprises a CpG island region of an ONECUT2 gene, a CpG island region of a DMRTA2 gene and a kit for detecting urinary tract epithelium cancer. The CpG island region of the ONECUT2 gene is located in chr18: 57441548-57441674, and the CpG island region of the ONECUT2 gene is located in The CpG island region of the DMRTA2 gene is located in chr1: 50418714-50418823, and the CpG island region of the DMRTA2 gene is located in chr1: The kit for detecting urothelial carcinoma comprises a first primer pair and a first probe which are used for specifically detecting the methylation state of the CpG island region of the ONECUT2 gene in the claim 1, and a second primer pair and a second probe which are used for specifically detecting the methylation state of the CpG island region of the DMRTA2 gene. The urinary tract epithelium cancer detection marker composition based on ONECUT2 and DMRTA2 gene methylation has high sensitivity and high specificity, the sensitivity and the specificity are both 90% or above, early-stage and low-grade urinary tract epithelium cancer can be effectively detected, comprehensive coverage is achieved, and the urinary tract epithelium cancer detection marker composition is not only suitable for bladder cancer, but also suitable for upper urinary tract epithelium cancer such as renal pelvis cancer and ureter cancer.

The present invention provides a method for detecting the presence of or risk of bladder cancer in a female patient, the method comprising the steps of: detecting the presence of a biomarker panel in a sample isolated from a female patient, the biomarker panel comprising IL-13 and IL-12p70 and one or more biomarkers selected from the group consisting of BTA, midkine, PAI-1 / tPA, 8OHdG, CEA, CK18, Fibrillin, Creatinine, CXCL16, Cystatin B, Cystatin C, d-dimer, EGF, FAS, HAD, IL-1a, IL-1b, IL-4, IL-6, IL-7, IL-8, MCP-1, Microalbumin, MMP9 NGAL, MMP9 TIMP1, NGAL, NSE, Progranulin, TUP, TGFB1, Thrombomodulin, sTNFR1, TPA, VEGF and Triglyceride, and / or the concentration of albumin / microalbumin / protein to creatinine in a sample isolated from a female patient, expressed as an albumin:creatinine ratio; and assessing the result and comparing it to a normal control, wherein an increase in the presence of the biomarkers compared to the normal control indicates the presence or risk of cancer in the patient from which the sample was isolated.

Disclosed are compositions and methods for detecting, prognosing, grading, and treating a cancer such as, for example a bladder cancer including, but not limited to upper tract urothelial carcinoma (UTUC) using circulating tumor DNA (ctDNA).

The application relates to the field of biological preparations, and particularly discloses an immunochromatographic reagent for detecting malignant tumors in urine and application thereof, which is used for solving the problems of poor recognition of tumor specific epitopes, heavy background interference, spectrum overlap and high subjectivity of artificial judgment in the single staining and color development of acridine orange in the detection of urinary exfoliative cells of bladder cancer. The color development reagent comprises A reagent, B reagent, C reagent and D reagent. The A reagent is provided with an antibody complex for target antigens of bladder tumor cells in urine exfoliation and acridine orange. The B reagent comprises a fluorescently labeled secondary antibody composition corresponding to the A reagent and an enzyme-labeled secondary antibody-tyramide deposition amplification composition. In the application, AI imaging analysis is adopted to calibrate layered recognition labels and acridine orange staining negative and positive labels. Through multi-target immunochromatography, two sets of color separation amplification schemes and AI imaging analysis, the application improves the recognition ability of bladder tumor specific epitopes, the image quality and the image analysis accuracy in the detection of urinary exfoliative cells.

The present application relates to the field of polymer chemistry and biomedical technology, and particularly relates to a macrocyclic lactone polymer shown in formula (I) which is used for preventing or treating hyperproliferative diseases, including liver cancer, leukemia, breast cancer, colon adenocarcinoma, gastric cancer, lung cancer, Barrett's esophageal cancer, cervical cancer, pancreatic cancer, endometrial cancer, bone cancer, lymphoma, kidney cancer, brain cancer, nerve cancer, nasopharyngeal cancer, oral cancer, bladder cancer, colorectal cancer and melanoma, and has the potential to be developed into a new type of antitumor drug.

A taxane composition and use thereof. The taxane composition is a taxane aqueous composition comprising a taxane. The taxane aqueous composition is used for treating an individual with bladder cancer by means of intravesical instillation, and has at least one of the following characteristics: (1) at least about 5% of the taxane is free taxane; and (2) the concentration of the free taxane is about 0.01 mg / ml to about 0.8 mg / ml. Alternatively, the taxane aqueous composition is used for treating a bladder cancer patient by means of intravesical instillation; after the taxane aqueous composition is administrated to the bladder cancer patient, the taxane in the plasma of the bladder cancer patient has at least one of the following characteristics: (1) the concentration of the taxane in the plasma of the bladder cancer patient is at least about 0.02 ng / ml; and (2) the AUC of the taxane in the plasma of the bladder cancer patient is at least about 0.02 h*ng / mL.

The invention belongs to the technical field of biomedicine, and relates to a human bladder cancer cell line ZSZB1 with primary cis-platinum drug resistance and application thereof. The cell line is preserved in the China Center for Type Culture Collection (CCTCC), the preservation number is CCTCC No: C2024120, and the cell line is derived from a radical operation specimen of primary chemotherapy drug-resistant bladder cancer patients of Chinese population, and has stable in-vitro multiplication capacity and primary cis-platinum drug-resistant characteristic. The ZSZB1 provides an ideal experimental model for bladder cancer pathogenesis research, cis-platinum drug resistance mechanism exploration and novel antitumor drug screening. Establishment of the cell line can effectively promote transformation from basic research of bladder cancer to clinical application, and the cell line is of great significance to promotion of precise medical development.

Aspects of this invention are related to the use of N-desmethyl ruboxistaurin and pharmaceutically acceptable formulations thereof to modulate RSK signaling. Some aspects of the invention relate to the use of N-desmethyl ruboxistaurin to inhibit RSK. Some aspects of the invention provide methods of using N-desmethyl ruboxistaurin in the treatment of subjects with cancer, including breast cancer, ovarian cancer, prostate cancer, lung cancer, hepatocellular carcinoma, colorectal cancer, melanoma, osteosarcoma, myeloproliferative neoplasms, leukemia, and bladder cancer. The disclosed methods extend beyond disease treatment, including supportive care during radiation chemotherapy and prevention of cancer relapse. N-desmethyl ruboxistaurin administration, alone or in combination with other cancer therapies, inhibits RSK and shows a safety profile that supports its long-term use.

The present invention provides methods for treatment of high-risk non-muscle invasive bladder cancer that is unresponsive to BCG therapy by locally administering gemcitabine to the bladder. Also provided herein are kits and articles of manufacture for treating high-risk non-muscle invasive bladder cancer that is unresponsive to BCG.

The invention belongs to the technical field of medical artificial intelligence, and particularly discloses a prediction method of urinary system cancer categories and an evaluation method of biomarkers of the urinary system cancer categories. According to the method, a feature extraction algorithm and a Raman attention neural network are developed aiming at the SERS spectrum of urine, a healthy control group, a benign urinary disease group, a bladder cancer group, a kidney cancer group and a prostate cancer group are successfully distinguished, and the overall accuracy rate is 94.87%. In particular, the invention provides a method for evaluating biomarkers of cancer classes of the urinary system, successfully reveals that cancer diagnosis depends on differences of specific biomarker levels, and determines effective biomarkers of cancers. Research finds that most biomarkers are positively correlated with positive prediction, and the cancer specific biomarkers are particularly important, which provides important guidance for the clinical basis fuzzy problem of the current novel disease diagnosis technology.

The present invention discloses a reagent kit and method for detecting bladder cancer. The reagent kit includes a DHFR PCR reaction mixture, Twist1 and TSC21 PCR reaction mixtures, a point mutation positive control, a methylation positive control, and a negative control. The present invention detects point mutations in the DHFR gene and the methylation levels in the promoter regions of the TSC21 and Twist1 genes in a sample, thereby achieving combined detection of gene point mutations and methylation and determining whether or not a sample has become cancerous. The present invention is easy to operate, simple to use, has high detection sensitivity, and good specificity, and is therefore of great significance in the detection of bladder cancer.

The invention discloses application of a PAPSS2 inhibitor in preparation of a medicine for treating bladder cancer. Based on the principle that PAPSS2 inhibits p53 expression through sulfurylation modification and mediates purine metabolism reprogramming to promote bladder cancer progress, a sulfurylation rate-limiting enzyme PAPSS2 is used as a core target spot for bladder cancer treatment, the target spot is a key upstream molecule for regulating purine metabolism reprogramming, and high expression of the target spot is directly related to poor prognosis of bladder cancer; the PAPSS2 inhibitor is adopted to specifically inhibit expression or activity of PAPSS2, so that the pathway is intervened to block a metabolic reprogramming process of bladder cancer, and the core is to inhibit PAPSS2-mediated p53 sulfurylation modification and recover an inhibition function of p53 on purine metabolism. According to the invention, the feasibility and effectiveness of bladder cancer metabolism targeted therapy are obviously improved.

The invention discloses a staurosporine glucoside derivative as well as a preparation method and application thereof, and belongs to the field of medicine synthesis. C3-NHCH3 of staurosporine is subjected to glycosylation modification, and the staurosporine glycoside derivative shown in the formula (I) is prepared. The glycoside derivative prepared by the invention has a better inhibition effect on human acute myeloid leukemia cells THP-1, human bladder cancer cells 5637, human colon cancer cells HCT-116, human pancreatic cancer cells PATU8988T and human liver cancer cells HuH-7, and the compound 5 also has an excellent inhibition effect on human gastric cancer cells MKN-45. A candidate compound is provided for development of drugs for bladder cancer, colon cancer, pancreatic cancer, liver cancer, stomach cancer or acute myeloid leukemia.

The present application relates to the technical field of in-vitro diagnosis, and in particular to a cell detection kit for the abnormality of human chromosomes 3 and 10 and a use thereof. A probe set comprised in the kit uses a specific chromosome locus or a centromere as a target, or uses a combination of a plurality of specific chromosome loci or centromeres as a target, so that the kit can rapidly and effectively detect a variety of cancer samples comprising lung cancer, breast cancer, intestinal cancer, esophageal cancer, bladder cancer, liver cancer, gastric cancer, pancreatic cancer, ovarian cancer, cervical cancer or prostate cancer, and is suitable for cancer diagnosis and development and popularization of prognostic products.

Indivi dualized neoantigen vaccines, as well as methods for their use in subjects to treat urothelial orbladder cancer are provided. In some embodiments, individualized neoantigen vaccines are used with an immune checkpoint inhibitor and optionally enfortumab vedotin to treat a urothelial or bladder cancer after surgical resection. Prior to surgical resection, in some embodiments, the subject is administered a neoadjuvant therapy comprising an immune checkpoint inhibitor, individualized neoantigen vaccines, and, optionally, enfortumab vedotin.

The invention discloses a fluorescent reagent composition for detecting hyaluronidase and application thereof, and is characterized in that the fluorescent reagent composition comprises a sodium hyaluronate or hyaluronic acid solution, a magnetic nano material Fe3O4NPs solution and a fluorescent nano material UCNPs solution, the detection of hyaluronidase comprises the following steps: adding a to-be-detected urine sample containing hyaluronidase into a sodium hyaluronate solution to degrade sodium hyaluronate; adding a fluorescent nano-material UCNPs solution into the reaction product, enabling the fluorescent nano-material UCNPs solution to generate electrostatic adsorption with the unhydrolyzed sodium hyaluronate, and outputting a fluorescent signal F0; adding a magnetic nano material Fe3O4NPs solution for magnetic separation, and taking supernate to measure a fluorescence signal F; calculating the concentration of hyaluronidase in the urine sample to be detected by taking F / F0 as an output signal; the kit has the advantages of high sensitivity, strong specificity, high accuracy and simplicity in operation, and is used for ultra-sensitive detection of the bladder cancer biomarker HAase.

The invention provides a cancer diagnosis model development method. The cancer diagnosis model development method comprises the steps of constructing a training set and establishing a diagnosis model on the training set. The training set includes miRNA expression profiles from non-cancer subjects and cancer patients having two or more cancer types, and establishing the diagnostic model includes calculating a diagnostic index based on a selected miRNA biomarker set, the selected miRNA biomarker set being obtained from a miRNA ranking in a differential expression analysis of the miRNA expression profiles in the training set. Methods of detecting a target cancer by means of the diagnostic model so developed are also provided. A 4-miRNA-based diagnostic model shows high performance in a verification set, and can realize the sensitivity greater than or equal to 0.98 while maintaining the specificity of 0.99 when detecting various cancers including lung cancer, gastric cancer, biliary tract cancer, bladder cancer, prostate cancer and glioma.

The invention relates to application of CD8 + Tcm in preparation of a product for evaluating sensitivity of a PD-1 inhibitor to cancer treatment. The scRNA-seq is utilized to comprehensively characterize the influence of PD-1 inhibitor treatment on bladder cancer tumor microenvironment, reveal the cytodynamics and molecular characteristics of bladder cancer during PD-1 inhibitor treatment, and highlight the potential of CD8 + Tcm cells as immunotherapy curative effect prediction biomarkers. In addition, SFRP2 + CAF is a key marker for immunotherapy drug resistance, and IFIT1 + neutrophil is a key marker for immunotherapy sensitivity. The invention deepens the understanding of the potential PD-1 treatment drug resistance mechanism of the bladder cancer patient in the prior art, provides a theoretical basis for optimizing the bladder cancer immunotherapy strategy, and provides a new direction for the potential immunotherapy target of the bladder cancer.

The invention provides a UBC-CK8 / 18 detection kit based on chemiluminescence, and the kit is characterized in that an antibody is immobilized through a streptavidin-biotin system to form a magnetic bead-biotinylated antibody-antigen-acridinium ester labeled antibody compound; after washing, the substrate solution excites the acridinium ester to generate a photon signal, and a relative luminescence unit (RLUs) is captured by a full-automatic chemiluminescence immunoassay instrument, so that rapid and low-cost clinical detection of bladder cancer is realized, and the detection performance is good.

This invention discloses an electrochemical-fluorescence dual-mode biosensor for the detection of bladder cancer-related miRNA biomarkers and its application. The sensor is a homogeneous biosensor comprising a CRISPR / Cas13a system for specific recognition of target miRNAs, magnetic beads, multiple nucleic acid substrates, and one or more signal probes. The CRISPR / Cas13a system includes the Cas13a protein and crRNA with a complementary sequence to the miRNA. The magnetic beads bind to nucleic acid substrate 1, serving as the reaction substrate. After activation by the target miRNA, the CRISPR / Cas13a system trans-cleaves the ribonucleotide sites in the nucleic acid substrate 1 sequence bound to the magnetic beads. Magnetic separation of the magnetic beads and supernatant forms a dual-sensing circuit. The dual-sensing circuit reacts with different substrate nucleic acids and signal probes respectively, outputting electrochemical and fluorescence response signals, achieving single-shot dual-mode detection of the target miRNA.

The invention discloses a urine exosome miRNA (micro Ribonucleic Acid) marker combination and a kit for diagnosing bladder cancer. The marker combination is composed of three kinds of miRNAs with different biological functions, and comprises hsamiR-196a-5p and hsamiR-130b-3p which are expressed in the bladder cancer in an up-regulated manner, and hsamiR-124-3p which is expressed in a down-regulated manner in the bladder cancer in an up-regulated manner in the bladder cancer in an up-regulated manner in the bladder cancer in the bladder cancer in an up-regulated manner. On the basis, the invention also provides a primer combination for detecting the three miRNAs and a kit containing the primer combination. The invention is suitable for diagnosing and monitoring bladder cancer.

The application provides a chiral 2-position disubstituted indoline compound and a synthesis method and application thereof. The application uses a simple structure palladium catalyst and a chiral ligand as a catalyst system, and uses a newly designed allyl benzoxazinone as a raw material to perform a palladium catalyzed intramolecular asymmetric cyclization reaction, so that efficient asymmetric synthesis of the chiral 2-position disubstituted indoline compound is realized. The synthesis method is simple, the reaction condition is mild, the cost is low, and the efficiency is high; the raw material is cheap and easy to obtain, atom economy is good, and the substrate is widely applicable; the target product has high yield and high enantioselectivity; the chiral 2-position disubstituted indoline compound obtained by the application has excellent inhibition effect on bladder cancer cells, provides a scientific basis for developing a new candidate drug for treating bladder cancer, and has important significance for the treatment of bladder cancer.

The invention discloses a bladder cancer early screening method based on plain-scan CT and MRI time sequence fusion, which realizes high-precision lesion recognition and positioning under the condition of low-dependence enhanced scanning through knowledge distillation and bimodal feature fusion. The method comprises the following steps: constructing a multi-modal data set including plain scanning, arteriovenous phase enhanced CT and MRI; a key frame sparse annotation and linear interpolation complementation strategy is adopted to reduce the annotation cost; performing preprocessing such as window level adjustment, normalization and zooming on the image; a CT / MRI recognition and positioning network is constructed, each sub-network comprises a 2D positioning branch and a 3D classification branch, and the characterization capability of plain scanning data is enhanced through a teacher-student knowledge distillation mechanism; and finally, integrating the bimodal information through a feature fusion module, and outputting a classification and positioning result. According to the method, time sequence consistency and modal consistency constraints are introduced, the recognition robustness of small focus and unclear boundary areas is improved, the manual film reading burden is remarkably reduced, the screening efficiency and safety are improved, and the method is suitable for early large-scale screening scenes of bladder cancer and has important clinical popularization value.

The invention relates to the technical field of preparation of anti-cancer drugs, in particular to a temperature-sensitive hydrogel delivery drug based on an ALDH1 inhibitor and a preparation method and application of the temperature-sensitive hydrogel delivery drug. The thermo-sensitive hydrogel delivery drug is formed by compounding an ALDH1 inhibitor entrapment core, a tumor targeting modification layer and a thermo-sensitive hydrogel matrix system, and through triple technology integration, the defects that an existing delivery system is insufficient in targeting, uncontrollable in drug release and the like are overcome. The delivered drug can significantly inhibit the activity of tumor stem cells, reduce the toxicity of organs, and provide a new scheme for precise treatment of bladder cancer.

The invention discloses an application of a compound as a CYP2E1 inhibitor, which is characterized in that the compound or a salt thereof as an inhibitor takes CYP2E1 as a target spot and is combined with the CYP2E1, and the CYP2E1 inhibitor has an inhibition effect on CYP2E1. The inhibitor can be used for preventing and treating tumors such as liver cancer, glioma, ovarian cancer, bladder cancer and gallbladder cancer. Similarly, the inhibitor can also be used for preventing and treating other inflammation-related diseases such as liver injury, fatty liver, hepatitis, hepatic fibrosis, rheumatic and rheumatoid arthritis, sepsis, Alzheimer's disease, ischemic cerebral apoplexy, Parkinson's disease, hyperlipidemia, atherosclerosis, coronary heart disease, diabetes mellitus and the like.